Table 3.

Median and interquartile range within-person change in PTHM from baseline to week 12 in FACT participants by treatment arm

400 μg FAPlaceboTest for group difference
PTHMMedian (IQR)Median (IQR)PFDRa
All participants
 H3K36me2b−0.05 (−0.39, 0.11)−0.15 (−0.43, 0.11)0.80
 H3K36me3c0.02 (−0.28, 0.27)0.02 (−0.23, 0.30)0.80
 H3K79me2d−0.06 (−0.28, 0.14)−0.05 (−0.24, 0.04)0.80
Males
 H3K36me2e−0.06 (−0.31, 0.11)−0.07 (−0.44, 0.16)0.80
 H3K36me3f0.00 (−0.28, 0.23)0.05 (−0.23, 0.47)0.80
 H3K79me2g−0.03 (−0.19, 0.21)−0.03 (−0.28, 0.09)0.80
Females
 H3K36me2h−0.05 (−0.44, 0.10)−0.17 (−0.37, 0.04)0.80
 H3K36me3i0.04 (−0.31, 0.28)0.02 (−0.22, 0.12)0.80
 H3K79me2j−0.13 (−0.47, 0.08)−0.05 (−0.18, 0.04)0.80
  • Abbreviation: IQR, interquartile range.

  • aP from Wilcoxon rank-sum test for treatment group difference.

  • b400 μg folic acid, n = 103; placebo n = 56.

  • c400 μg folic acid, n = 98; placebo n = 55.

  • d400 μg folic acid, n = 97; placebo, n = 56.

  • e400 μg folic acid, n = 52; placebo, n = 27.

  • f400 μg folic acid, n = 50; placebo, n = 28.

  • g400 μg folic acid, n = 50; placebo, n = 29.

  • h400 μg folic acid, n = 51; placebo, n = 29.

  • i400 μg folic acid, n = 48; placebo, n = 27.

  • j400 μg folic acid, n = 47; placebo, n = 27.